Skip to content

Enabling affordable, accurate and accessible CRISPR diagnostics at the point-of-need

Revolutionary technology expanding global access to diagnostics

SHERLOCK utilizes a groundbreaking method for the amplification of nucleic acid targets, performing the entire amplification and detection process at ambient temperature and without instrumentation.

Developed by our Co-Founder Jim Collins’ lab at Wyss Institute and MIT, Sherlock’s exclusive world-wide license from Harvard University’s Office of Technology Development (OTD) enables simple-to-use, portable, and ultra-sensitive diagnostics for infectious disease detection in low-resource settings.

A unique combination for diagnostics delivery

Coupled with our CRISPR-based SHERLOCK platform, our method enables robust amplification of DNA and RNA sequences with high sensitivity and specificity without strict temperature requirements or complex laboratory instrumentation. This innovation advances instrument-free diagnostic assays that can detect a specific nucleic acid sequence at the point-of-need.

High Specificity

Proprietary Cas-enzymes programmed to detect target sequences with high specificity

High Sensitivity

Proprietary amplification method enables high sensitivity

Low Complexity Instrumentation

Rapid amplification of target sequences at room temperature without complex laboratory equipment

Low Cost of Goods

Detectable by fluorescent, colorimetric or lateral flow readouts

Contact us to learn more about how we are engineering biology to test anywhere, everywhere.